An essential receptor for adeno-associated virus infection
Open accessThe DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus (AAV) vectors are currently the leading candidates for virus-based gene therapies because of their broad tissue tropism, non-pathogenic nature and low immunogenicity. They have been successfully used in clinical trials to treat hereditary diseases such as haemophilia B (ref. 2), and have been approved for treatment of lipoprotein lipase deficiency in Europe. Considerable efforts have been made to engineer AAV variants with novel and biomedically valuable cell tropisms to allow efficacious systemic administration, yet basic aspects of AAV cellular entry are still poorly understood. In particular, the protein receptor(s) required for AAV entry after cell attachment remains unknown. Here we use an unbiased genetic screen to identify proteins essential for AAV serotype 2 (AAV2) infection in a haploid human cell line. The most significantly enriched gene of the screen encodes a previously uncharacterized type I transmembrane protein, KIAA0319L (denoted hereafter as AAV receptor (AAVR)). We characterize AAVR as a protein capable of rapid endocytosis from the plasma membrane and trafficking to the trans-Golgi network. We show that AAVR directly binds to AAV2 particles, and that anti-AAVR antibodies efficiently block AAV2 infection. Moreover, genetic ablation of AAVR renders a wide range of mammalian cell types highly resistant to AAV2 infection. Notably, AAVR serves as a critical host factor for all tested AAV serotypes. The importance of AAVR for in vivo gene delivery is further highlighted by the robust resistance of Aavr(-/-) (also known as Au040320(-/-) and Kiaa0319l(-/-)) mice to AAV infection. Collectively, our data indicate that AAVR is a universal receptor involved in AAV infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The peptide insertion at position R588 in R100 sterically prohibits the close proximity between R585 and R588 required for heparan sulfate binding ( Fig. 5 B), suggesting a plausible mechanism for enhanced transit through the heparan sulfate-rich ILM barrier.”
From Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies (2024) · cites this paper as [45]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Maxfield, F. R., & McGraw, T. E. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1315 · Cited by 1,729
Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Summerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406
Ebola virus entry requires the cholesterol transporter Niemann–Pick C1
Carette, J. E., Raaben, M., Wong, A. C., Herbert, A. S., Obernosterer, G., Mulherkar, N., Kuehne, A. I., Kranzusch, P. J., Griffin, A. M., Ruthel, G., et al. (2011) · Nature · doi:10.1038/nature10348 · Cited by 1,303
Self-citationMannose 6-phosphate receptors: new twists in the tale
Ghosh, P., Dahms, N. M., & Kornfeld, S. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1050 · Cited by 1,086
A Versatile Viral System for Expression and Depletion of Proteins in Mammalian Cells
Campeau, E., Ruhl, V. E., Rodier, F., Smith, C. L., Rahmberg, B. L., Fuss, J. O., Campisi, J., Yaswen, P., Cooper, P. K., & Kaufman, P. D. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006529 · Cited by 964
Cited by
Items 401–500 of 524
Meng, Q., Guo, M.-H., Zhang, R., Wei, J., Chen, Q., Zhao, X., Xu, C., Wu, Y., Kuai, J., Zhao, J., et al. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01621-8 · Cited by 3
“AAV vectors have been widely used for transgene expression in animal models and gene therapies in human clinical trials because of their unique safety features and high ef fi ciency of infection [54].”
Terada, T., Fujii, S., Yamanishi, N., Kajihara, R., Watanabe, T., Ezaki, R., Horiuchi, H., & Matsuzaki, M. (2025) · Journal of Virological Methods · doi:10.1016/j.jviromet.2025.115263 · Cited by 2
Naskar, R., Pal, P., Parsa, K. V. L., Paul, B., Oruganti, S., & Chakraborty, S. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148553 · Cited by 2
Development of Next-Generation Muscle Gene Therapy AAV Vectors
Nance, M. E., & Duan, D. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_11 · Cited by 2
Hearing impairment: new frontiers of regenerative medicine
Franzè, A., Miceli, M., VECCHIO, V. D., Auletta, G., Laria, C., Malesci, R., & Marciano, E. (2021) · Otorhinolaryngology · doi:10.23736/s2724-6302.21.02381-1 · Cited by 1
Lilja, A., Finkel, Y., Aharon, E., Nachshon, A., Schwartz, M., & Stern‐Ginossar, N. (2025) · Nature Protocols · doi:10.1038/s41596-025-01242-9 · Cited by 1
Gene Electrotransfer and DNA Sensing
Heller, L. C. (2025) · Bioelectricity · doi:10.1177/25763113251377427 · Cited by 1
“106 Viralvectors used for gene therapy, such as adenovirus, 107 adeno-associated virus, 108 and lentivirus, 109 use receptor-mediated endocytosis for cell entry.”
Interrogating the dependency of AAV capsids on AAVR for retinal transduction
Hinsch, V. G., Kellish, P. C., Xu, E. M., Fajardo, D., McLaughlin, K., Kiel, K. N., Peterson, J. J., Friend, H. L., Boye, S. L., & Boye, S. E. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201677 · Cited by 1
“8 Due to degenerative alleles in Pde6b and Bfsp2 of this model, both of which affect vision, the mice were crossed to B6 (C57BL/6J) mice for two generations to breed out the degenerative alleles.”
Nelson, A. T., Smith, A., Curley, C. T., Kelly, B., Ganesh, A. N., Peterson, D., Fabyanic, E. B., Kostuk, E. W., Weber, T., & Engel, E. A. (2026) · Human Gene Therapy · doi:10.1177/10430342251411044 · Cited by 1
“Interestingly, the VR1 loop has also been found to interface with AAVR, 15 which is a critical cellular factor required for AAV9 transduction, 20 suggesting that VR1 mutagenesis could impair transduction by interfering with AAVR binding.”
Species barriers in AAV tropism: mechanisms, models, and emerging solutions for clinical translation
Xu, X. (2026) · Acta Biochimica Polonica · doi:10.3389/abp.2026.15939 · Cited by 2
From CRISPR functional genomics to synthetic interventions: engineering antiviral strategies
Qiao, W. (2026) · Journal of Virology · doi:10.1128/jvi.00057-26 · Cited by 1
“Functional genomics has revealed that delivery efficiency, tissue tropism, and expression durability are governed by host genetic determinants, directly linking CRISPR-derived maps to delivery design (131, 132).”
Lin, N., Mavropoulos, S., & Ishikawa, K. (2026) · Human Gene Therapy · doi:10.1177/10430342261462309 · Cited by 1
“24 Once internalized, only a fraction of particles escape the endosomal system and reach the nucleus, 25,26 whereas HYPERTHERMIA-ENHANCED AAV GENE THERAPY many are routed to late endosomes/lysosomes and to proteasome-dependent degradation.”
Gene Therapy for Neurological Disorders: Molecular Approaches for Targeted Treatment
Malviya, R., Singh, A. K., Goyal, P., & Sundram, S. (2024) · Apple Academic Press eBooks · doi:10.1201/9781003494102 · Cited by 1
A versatile cell line for establishing potency of cell type-specific AAV transgenes
Martinez, R. A., Bishaw, Y. M., Quinlan, M. A., Groce, E. L., Gore, B. B., Lein, E. S., Mich, J. K., & Levi, B. P. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101401 · Cited by 1
Electrophysiology in neuropathic pain: a bibliometric analysis and literature review
Cui, Y., Lv, C., Yan, W., Zhang, L., Sun, N., Zhang, X., & Zhong, Z. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1616973 · Cited by 2
Uhl, L. K., & Fasina, O. O. (2025) · Viruses · doi:10.3390/v17070984 · Cited by 2
Identification of TPRA1 as a Novel Receptor and Predictive Biomarker for Oncolytic Virus M1
Hu, L., Zhang, G., Lin, Y., Yi, S., Yang, H. J., Lin, X., Song, D., Liu, Z., Zhang, J., Zeng, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202510597 · Cited by 1
Multi-omics analysis delineates molecular signatures of spinal ependymal tumor
Liu, W., Ning, C., Geng, X., Wang, B., Zhang, Y., Wang, C., Liu, Y., Zheng, G., Wang, Y., Wang, X., et al. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01122-0 · Cited by 1
“We speculated that the fusion of KIAA0319L and PARK7 results in a protein that integrates the endocytosis capabilities of KIAA0319L [24 ] with PARK7 , an enzyme mutated in hereditary Parkinson’s disease, [25] potentially influenc - ing SP-EPN_6 cellular responses to oxidative stress (Sup -…”
Dzhashiashvili, Y., McBride, J. L., Fabyanic, E. B., Huang, X., Kelly, B. M., Walton-Gibbs, G. D., Vemireddi, V., Wicks, J. R., Nayal, M., Hippen, A. A., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.009 · Cited by 1
Marco, S., Fernández, M., Honorato, B., Juanarena, N., Sainz, C., Andueza, A., Gould, D., Anderson, S., de Andrea, C., Domínguez, P. P., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.02.013 · Cited by 1
AAV transduction of human glioblastoma cell lines induces perturbation in cell proliferation
Wu, A. J., Dumo, C. J., Cook, W. H., Richards, I., Foliaki, J. M., Cooper, E., Fong, D. M., Mouravlev, A., Park, T. I., Dragunow, M., et al. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201216 · Cited by 1
Efficient and safe transduction of cochlear outer hair cells in adult mice with AAV2.7m8-Myo15
Wang, W., Dai, X., Wang, D., Ma, P., Gao, W., Xu, X., Qi, J., Chai, R., & He, Z. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.07.040 · Cited by 1
CA-IV-directed small-molecule shuttle enables targeted brain delivery of biologics
Ding, X., Chen, X., Boehm, P., Carretero‐Cerdán, A., Jang, S., Sullivan, E. E., Arokiaraj, C. M., Ristic, F., Kavvathas, B., Campos, L., et al. (2026) · Nature Chemical Biology · doi:10.1038/s41589-026-02294-y · Cited by 4
Nunes-Alves, C. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.22 · Cited by 1
Worgall, S., & Crystal, R. G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818422-6.00029-0 · Cited by 3
Vascular-targeted recombinant adeno-associated viral vectors for the treatment of rare diseases
Körbelin, J., Schwaninger, M., & Trepel, M. (2016) · Rare Diseases · doi:10.1080/21675511.2016.1220470 · Cited by 2
Viral infection: A key host receptor for AAV
Sun, S., & Schaffer, D. V. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2015.27 · Cited by 1
New innovations for ocular gene therapy
Igarashi, T., Miyake, K., Kobayashi, M., Takahashi, K., Nakamoto, K., Okada, T., & Takahashi, H. (2017) · Nihon Ika Daigaku Igakkai Zasshi · doi:10.1272/manms.13.88 · Cited by 2
Engineering of Novel Adeno-Associated Virus Vectors for Gene Therapy Applications
Ortiz, S., & Luis, J. (2016) · Cited by 1
Cox, B. C., Brigande, J. V., & Walters, B. J. (2023) · Springer handbook of auditory research · doi:10.1007/978-3-031-20661-0_8 · Cited by 1
Sutter, S. O., Jetzer, S., Lkharrazi, A., Pedersen, S., Schraner, E. M., Vogt, B., Büning, H., & Fraefel, C. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.08.574727 · Cited by 1
AAV Capsid Screening for Translational Pig Research Using a Mouse Xenograft Liver ModelPreprint
Willimann, M., Tiyaboonchai, A., Adachi, K., Li, B., Waldburger, L., Nakai, H., Grompe, M., & Thöny, B. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.29.596409 · Cited by 1
“A majority of investigated AAV capsids use the common receptor known as the AAV receptor (AAVR, KIAA0319L) 60,61 , which has only limited expression in the liver 62 .”
BackgroundChiorini, J. A. (2016) · Oral Diseases · doi:10.1111/odi.12495
Is Age Just a Number? Accounting for Age When Designing Viral Vectors for Parkinson's Disease
Polinski, N. K. (2016) · Michigan State University Libraries · doi:10.25335/m5g462
Chemical Modulation of AAV Trafficking
Berry, G. E. (2016) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/dpe3-gy73
Biology of AAV Vectors in the Central Nervous System
Murlidharan, G. (2016) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/cr64-be62
Fong, D. M., Wu, A. J., & Young, D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809813-4.00002-8 · Cited by 1
Novel Approaches for Pluripotent Reprogramming
Weltner, J. (2018) · Helda - University of Helsinki Institutional Repository · Cited by 1
On the entry and entrapment of picornaviruses
Staring, J. (2018) · Utrecht University Repository (Utrecht University)
DETERMINANTS OF AAV TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER
Albright, B. H. (2018) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/vnpr-wx33
Adeno-associated virus-mediated gene therapy in central nervous system genetic disorders
Casy, W., Ling, Q., Shaffo, F. C., Sinnett, S. E., & Gray, S. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813955-4.00010-6 · Cited by 1
マルチトーン信号のピーク対平均電力比(PAPR)を低減する初期位相設定法
楢橋, 祥., & 野島, 俊. (1995) · Cited by 3
Benefits and Shortcomings of Laboratory Model Systems in the Development of Genetic Therapies
Bucher, K., Rodríguez‐Bocanegra, E., & Fischer, M. D. (2022) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1757-9879
Conboy, I. M. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732227244.793553939
(2016) · Nature Biotechnology · doi:10.1038/nbt.3499
Fehlings, M. G. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734958350.793573257
Parvovirus Vectors: The Future of Gene Therapy
Gupta, M. (2023) · Veterinary medicine and science · doi:10.5772/intechopen.105085
Interactions of parvoviruses with the cellular DNA damage response and CTCF
Boftsi, M. (2021) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/90982
Silveria, M. (2022) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/94095
Dengue Virus Gene-Silencing Techniques: A Current Assessment
Casseb, S. M. M., Melo, K., Santos, C., & Franco, E. C. D. S. (2023) · Infectious diseases · doi:10.5772/intechopen.110421
Blood-brain barrier-directed gene therapy as a strategy to treat Niemann-Pick type C2 disease
Rasmussen, C. L. M. (2022) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau528833295
Benyamini, B., Esbin, M. N., Whitney, O. N., Walther, N., & Maurer, A. C. (2023) · doi:10.3791/65572-v
Recombinant Adeno-Associated Viral Vector Transduction of Human Prostate Cancer Cell Lines
Batır, M. B. (2023) · Celal Bayar Üniversitesi Fen Bilimleri Dergisi · doi:10.18466/cbayarfbe.1336250
Saad, N. Y. (2024) · Nucleic Acid Insights · doi:10.18609/nai.2024.011
Li, L., Qin, R., Liu, Y., Tseng, Y.-S., Zhang, W., Yu, L., Mietzsch, M., Zou, X., Liu, H., Lu, G., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012260
Глебовна, Г. А., Анатольевна, Е. М., Frolov, G. S., Zubrinkin, D. A., Hisamutdinov, A., Garipov, L. N., Mingaleev, D. N., & Ravilov, R. K. (2024) · Agrarian science · doi:10.32634/0869-8155-2024-383-6-39-43
Molecular concepts for pandemic viruses : membrane fusion assays and targeting of reservoir cells
Theuerkauf, S. A. (2024) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.86442
Adeno-associated virus-mediated gene therapy in central nervous system genetic disorders
Ling, Q., Boitnott, A., Garza, I. T., Casy, W., Shaffo, F. C., Sinnett, S. E., & Gray, S. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19041-4.00007-8
Fleischmann, T. T. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2418961
“This cell line stably over-expresses the KIAA0319L gene, which enhances infection rates for AAV by a factor of ~10 or more, by expressing a universal type I transmembrane protein that directly binds AAV particles [12].”
A Highly Precise Method for the Quantitation of rAAV Cellular Uptake by ddPCR
Kiladjian, A., Pathak, P., Feschenko, M. S., Bergelson, S., Mason, C., & Wang, Y. (2025) · Human Gene Therapy · doi:10.1089/hum.2025.023
“18,19 Therefore, we investigated if using an AAVR stable cell line improves cellular uptake and thus decreases assay material requirements.”
Receptomics and Extracellular Interactomics for Biotherapeutic Characterization
Chandan, N. R., Ferrel, A., & Cao, S. (2025) · Wiley eBooks · doi:10.1002/9781394236145.ch17
AAV11 mediates efficient retrograde trans-neuronal transduction of astrocytesPreprint
Luo, N., Gao, Y., Han, Z., Xu, F., & Lin, K. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.10.681765
Species-specific AAVR dominates species-tropism of adeno-associated virus (AAV) vectorsPreprint
Kay, M. A., Jiang, Y., Liu, Y., Jing, Y., Zhang, F., & Lin, A. (2025) · Research Square · doi:10.21203/rs.3.rs-8198480/v1
“KIAA0319L or AAVR was identi�ed as an essential host factor for AAV transduction previously by the Carette group 7 .”
Meyer‐Berg, H., Zhou-Yang, L., Pilar de Lucas, M., Zambrano, A., Hyde, S. C., & Gill, D. R. (2020) · Figshare · doi:10.6084/m9.figshare.13141840
Cui, M., Cheng, S.-Y., Liang, J., McGowan, J., Xu, M., Xu, G., Luo, L., Wu, J., Harman, C. D., Jacobson, A. L., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.01.029 · Cited by 1
Vasquez, J. M., Mackey, H. L., Rostami, M. R., Leopold, P. L., & Crystal, R. G. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201709 · Cited by 1
“20,24,25 Deletion analysis has identified the first two PKD domains and the cytoplasmic tail as regions important for the support of AAVR-mediated AAV gene transfer.”
InfluentialMcCoy, J. C., Wallace, L. M., Zhou, B., Price, B., Salzman, R., & Harper, S. Q. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201727
Characterisation of AAV capsid-specific CD8+ T cell responses in human subjects
Vandamme, C. (2016) · theses.fr (ABES) · doi:10.70675/371e4bbfze69az417bz960azf9db02287546
Characterization of rAAV vectors packaging in baculovirusinfected insect cells
Penaud‐Budloo, M. (2018) · theses.fr (ABES) · doi:10.70675/c5cff6daz8fe4z430cz80e6z97a11cc59c8e
Sargent, D. (2018) · theses.fr (ABES) · doi:10.70675/2cd4ead6z0cd7z476dz8376z54bb3bd9a0ea
Thermostability of Adeno-Associated Virus (AAV) Vectors
Pacouret, S. (2018) · theses.fr (ABES) · doi:10.70675/33e13ef9z7aefz418dz8fdez21352cc194bc
Bartolo, L. (2018) · theses.fr (ABES) · doi:10.70675/b32b9711za15dz4740z8481z0ba7dd36e8ee
Etude de la réponse immunitaire virale préexistante anti-AAV chez l'homme
Xicluna, R. (2019) · theses.fr (ABES) · doi:10.70675/d2f47d7cz4f46z448cz85afz657c9516c86f · Cited by 1
Fibrose musculaire : acteurs cellulaires et stratégies thérapeutiques
Bensalah, M. (2019) · theses.fr (ABES) · doi:10.70675/26f11f97zd40az491cz93fcz9608314a2b03
Bella, T. L. (2018) · theses.fr (ABES) · doi:10.70675/e88d9a08za929z4c0fzb8d9z9f01cd69ca39
Development of safe and efficient aav vectors for retinal gene therapy
Khabou, H. (2018) · theses.fr (ABES) · doi:10.70675/aa896663z9772z4d87z9bd1z247af1f0e3f1
Modification chimique d’AAV pour la thérapie génique
Leray, A. (2021) · theses.fr (ABES) · doi:10.70675/c33b1ba2z6c22z40e1z9a98z3ed26b698b7a
Chassagne, J. (2019) · theses.fr (ABES) · doi:10.70675/74df0299z4167z4397zb93fz28bc889326f4
Preclinical gene therapy using recombinant AAV vectors in mouse models of two human diseases
Günes, Y. Ö. (2022) · theses.fr (ABES) · doi:10.70675/52c9a808z1652z42c4zae82zc812b95f1723 · Cited by 1
Gardin, A. (2023) · theses.fr (ABES) · doi:10.70675/ac839ccez52b2z45bez9294ze72731823d9b · Cited by 1
Structural studies of bk and jc polyomaviruses interactions with their receptors
Sorin, M. N. (2022) · theses.fr (ABES) · doi:10.70675/c914a691z5654z49d8z92f6z680dab7e105e
Nouvelle génération d’AAV : un mélange de chimie organique et de vectorologie
Lalys, P.-A. (2023) · theses.fr (ABES) · doi:10.70675/b6df86c2z6520z473ez9e10ze1740b9bc3ae
Etude des réponses T CD8+ après transfert de gène par rAAV ciblant le muscle
Jeanpierre, L. (2024) · theses.fr (ABES) · doi:10.70675/430aceacz50d2z426bz907dz876c55d1e935
Kumar, S. (2026) · Springer eBooks · doi:10.1007/978-981-95-7688-3_3
Mapping AAV capsid sequences to functions through function-guided in silico evolution
Guo, B., Zheng, H., Lin, X., Jiang, H., Mo, A., Wei, H., Zhang, R., Yuan, Y., Wu, Y., Li, H., et al. (2026) · Cell Press Blue · doi:10.1016/j.cpblue.2026.100016 · Cited by 3
Gene therapy for liver diseases: methods, challenges and opportunities
Yan, M., & Xiang, Q. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04518-8 · Cited by 1
“While AAV2 utilizes heparan sulfate proteoglycans, AAV8 and AAV9 bind the laminin receptor and require adeno-associated virus receptor (AAVR) (KIAA0319L) for cellular entry [165].”
Optimized AAV capsids robustly transduce airway epithelial cellsPreprint
Cooney, A. L., Chen, Y. H., Lewandowski, B. C., Lamer, S., Boysen, G., Kulhánková, K., Vu, A., Newase, P., Sinn, P. L., Davidson, B. L., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.10.723853
Allosteric Constraints on Rewiring Inducible RepressorsPreprint
Gupta, A., & Lewis, M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.2139/ssrn.6806711
Enhancing adeno-associated virus cellular entry through receptor engineeringPreprint
Dhungel, B. P., Nagarajah, R., Metierre, C., Yue, F., Kaiser, V., Bazley, H., Curry, C., Gokal, D., Sherman, A., Su, Q. P. P., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.26.727777
“AAVR BioID experiments identified several host factors directly regulating AAV transduction like AAVR2 10 , VPS51 9 and TFR1 21 or protein complexes involved in intracellular trafficking of AAV, such as the members of the solute carrier family 8,22,23 , Golgi-associated retrograde protein (GARP)…”
InfluentialShirokov, D., Lepekhina, D., Bogomiakova, M. E., Illarionova, S. E., & Lazarev, V. N. (2026) · Genes and Cells · doi:10.17816/gc705424
“Кроме того, недавно был обнаружен универсальный клеточный рецептор, участвующий в инфекции AAV, — AAVR [4]; однако данные о его взаимодействии с вирусом разнятся: он может участвовать как в интернализации на поверхности клетки, так и в связывании в ранней эндосоме или способствовать переходу из…”
Xie, S., Yang, Q., Jansen, L. V., Yao, B., Yang, G., Qu, K., Vader, P., Blok, C. S., de Jager, S. C. A., Boink, G. J. J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.27.727849
“Central to this architecture is the multivalent interaction between the AAV capsid and the AAV receptor– derived PKD1–PKD2 tandem domain (PKD12) 32-35 .”
GPLD1 is a scavenger carrier mediating lysosomal degradation of extracellular aberrant proteins
Tsuchiya, M., Yagishita, Y., Matsuura, A., & Itakura, E. (2026) · Life Science Alliance · doi:10.26508/lsa.202603717 · Cited by 1
“Nearly all vertebrate cells express a limited set of cell-surface HS proteoglycans, which serve as receptors for various growth factors and viruses (Yayon et al, 1991; Liu & Thorp, 2002; Xu & Esko, 2014; Pillay et al, 2016).”
Intracellular trafficking and nuclear compartmentalization of AAV gene delivery
Hutchinson, T. E., Singh, R. E., Oliver, J. Y., Davis, A., Potter, M., Hsi, J., Mietzsch, M., Bennett, A. D., & McKenna, R. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201770
“13,14 Recently, it has also been suggested that the trafficking of the virus occurs via the TGN, 15 which hosts both GPR108 and AAVR.”
Influential
Metadata
- Authors
- Pillay, S., Meyer, N. L., Puschnik, A. S., Davulcu, O., Diep, J., Ishikawa, Y., Jae, L. T., Wosen, J. E., Nagamine, C. M., Chapman, M. S., & Carette, J. E.
- Affiliations
- Stanford Medicine (US)
- Oregon Health & Science University (US)
- The Netherlands Cancer Institute (NL)
- Corresponding author
- Chapman, M. S.
- Carette, J. E.
- ORCID
- Venue
- Nature
- Published
- 2016-01-27
- Volume
- 530
- Issue
- 7588
- Pages
- 108-112
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4962915
- OpenAlex
- W2266837556
- Cited by
- 532
- References
- 33
- Citations by year
- 2026: 58 · 2025: 51 · 2024: 63 · 2023: 60 · 2022: 36 · 2021: 47 · 2020: 57 · 2019: 50 · 2018: 43 · 2017: 37 · 2016: 28
- FWCI
- 43.04
- Type
- journal article
- Language
- en
- Update notices
- erratum (2016-09-28)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (5u19ai109662-05)
- National Institute of General Medical Sciences (R01GM066875)
- National Institute of Allergy and Infectious Diseases (DP2AI104557, U19-AI109662)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Keywords
- adeno-associated virus, AAV receptor, AAV2, viral entry, host factors, endocytosis, AAV serotypes, gene therapy vectors, viral gene delivery
- MeSH terms
- Dependovirus, Animals, Antibodies, Cell Line, Endocytosis, Female, Humans, Male, Parvoviridae Infections, Receptors, Cell Surface, Receptors, Virus, Genetic Therapy, Gene Deletion, trans-Golgi Network, Mice, Virus Internalization, Viral Tropism, Host Specificity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.